

**Iowa Medicaid Pharmaceutical and Therapeutics Committee  
Minutes**

**Date:** August 15, 2024

**Chairperson:** Jason Kruse

Vice-Chairperson, Chuck Wadle, assisted in running the meeting as Jason Kruse was unable to attend.

**Time:** 9:30 a.m. to 11:35 a.m.

**Location:** Grimes State Office Building Room B100, 400 E 14th Street, Des Moines, IA 50319

**Committee Members Present:** Charles Wadle, D.O.; Jason Kessler, M.D.; Lacey Ferguson, Pharm.D.; Rachel Kinn, Pharm.D.; Tricia White, R.N. (via Zoom); and Jennifer Doudna, Pharm.D., R.Ph. (via Zoom). (Vacancies July 2023: 1 Physician, 1 Physician Assistant)

**Iowa DHHS Staff Present:** Abby Cate, Pharm.D., Pharmacy Consultant; and Darian Forcier, Pharmacy Administrative Support.

**Iowa Medicaid Staff Present:** Jacquelyn Hedlund, M.D., MS (via Zoom); Paige Clayton, Pharm.D. (via Zoom); Erin Halverson, R.Ph.; and Melissa Biddle.

**Managed Care Organization (MCO) Staff Present:** Jordan Thoman, Wellpoint Iowa; Emily Rogers, Iowa Total Care; and Candace Jordan, Molina Healthcare of Iowa.

Chuck Wadle called the meeting to order.

- I. Chuck Wadle asked that each committee and DHHS/Medicaid staff member introduce themselves to the public. Rachel Kinn made the motion to approve the April minutes, and Lacey Ferguson seconded. The motion passed with no objections. There were no new verbal conflict of interest disclosures. This will be Dr. Kessler's last meeting, and he was thanked for his years of service to the committee. Dr. Hedlund is also retiring at the end of August, so this will be her last meeting.
- II. PDL Revision Notifications (Erin Halverson): A fax blast sent to providers since the last P&T Meeting in April, to notify them of preferred drug list changes, was reviewed. Due to the resolution of availability issues for oseltamivir, Tamiflu capsules and Tamiflu oral suspension will become non-preferred on the PDL effective August 30, 2024.
- III. Drug Rebate Issues (Dr. Clayton): There are no issues to report, but Optum is monitoring the effects and trends of the AMP cap removal effective in January 2024, as PDL changes could arise due to manufacturers' responses to that change. CMS had originally predicted a 5% increase to the Medicaid budget, but it's looking like it will be more like 10-12%, particularly in some highly utilized areas. Optum staff have been working with manufacturers on supplemental rebates to attempt to bring down costs.
- IV. PA Criteria/Pro-DUR Edits (Dr. Cate): Committee members were provided copies of the informational letters sent to providers notifying them of Pharmacy Program and PDL changes

since the last meeting, including notice of reinstatement of member copays effective July 1, 2024, following the end of the Covid public health emergency (PHE) during which they had been removed. Opill oral contraceptive was added to the over-the-counter (OTC) covered drug list. The committee also received copies of the letters sent from the DUR Commission to DHHS following their meetings on May 1<sup>st</sup> and August 7<sup>th</sup>, the latter of which had recommended changes to the prior authorization criteria for: Antidiabetic Non-Insulin Agents; Biologicals for Axial Spondyloarthritis; and Biologicals for Plaque Psoriasis. Those recommendations have been approved by the state and will go into effect on October 1, 2024.

- V. Legislation (Dr. Cate): Pending CMS approval, DHHS was given a budget increase allowing for a change to the dispensing fee making it \$10.63 per prescription, separate from the ongoing cost of dispensing survey. There was also a change to Iowa Code Chapter 21, requiring committee meetings provide a hybrid or virtual/remote option for committee members as well as public attendees, so DHHS is working to set up options for meetings going forward.
- VI. Iowa Medicaid Updates (Dr. Cate): Iowa Medicaid received approval to move forward with a rule change to allow a 90-day supply per prescription, rather than the 31 days currently allowed. Effective October 1, 2024, this change will go into effect for certain reviewed drugs, mostly generic maintenance medications, and the list will be posted this month. A cost of dispensing survey was sent out to providers in May, with responses due back August 14, 2024. Data will be analyzed in preparation for the next legislative session and a proposed requested change to the dispensing fee.
- VII. Public Comment: In addition to the written public comments provided to committee members, they heard oral public comment from the speakers shown below. They were also forwarded manufacturer comments as they were received via email prior to the meeting.

<b>Name</b>	<b>Representing</b>	<b>Drug/Topic</b>
Derrick Grass	Novo Nordisk	Wegovy
David Kupperman	SpringWorks Therapeutics	Ogsiveo
Mary Claire Wohletz	Merck	Winrevair
Kevin Borth	Day One Biopharmaceuticals	Ojemda

Member Comments Received: None

Provider Comments Received: Winrevair, Winrevair, Winrevair

Manufacturer Comments Received: Adbry, Filsuvez, Opsynvi

At 10:04, Rachel Kinn motioned to go to closed session as authorized by Iowa Code Section 21.5(1)(a) of the Open Meetings Law to review or discuss economic records associated with the PDL which are required or authorized to be kept confidential. Jason Kessler seconded, and the motion passed with unanimous roll call approval. Open session resumed at 10:45.

VIII. PDL Discussion and Deliberation (Erin Halverson): All subsequent recommendations (with numbering as provided on agenda attachment 2) were made to maximize cost savings to the program unless otherwise noted.

1. Tradjenta to Preferred (removal of PA conditions)
2. Januvia to Preferred (removal of PA conditions)
3. Jentadueto to Preferred (removal of PA conditions)
4. Janumet to Preferred (removal of PA conditions)
5. Janumet XR to Preferred (removal of PA conditions)
6. Ventavis to Non-Preferred with Conditions.

Rachel Kinn motioned to accept the recommendations above, and Jason Kessler seconded. The decision was unanimous.

IX. Newly Released Drugs (Dr. Hedlund and Erin Halverson): All following recommendations (with numbering as provided on agenda attachment 3) were made to maximize cost savings to the program unless otherwise noted. Dr. Hedlund reviewed the clinical information for the new drugs, and then Erin Halverson read through the recommendations as follows:

1. Eohilia- Recommend status on the PDL as Non-Preferred
2. Filsuvez- Recommend status on the PDL as Non-Preferred
3. Ogsiveo- Recommend status on the RDL as Non-Recommended with Conditions
4. Ojemda- Recommend status on the RDL as Non-Recommended with Conditions
5. Opsynvi- Recommend status on the PDL as Non-Preferred with Conditions
6. Rezdiffra- Recommend status on the PDL as Non-Preferred
7. Rivfloza- Recommend status on the PDL as Non-Preferred
8. Spevigo Prefilled Syringe- Recommend status on the PDL as Non-Preferred
9. Voquezna- Recommend status on the PDL as Non-Preferred
10. Voquezna Pak- Recommend status on the PDL as Non-Preferred
11. Voydeya- Recommend status on the PDL as Non-Preferred
12. Wegovy- Recommend status on the PDL as Non-Preferred with Conditions (covered indication only: to reduce the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either obesity or overweight); DUR currently developing PA criteria.
13. Winrevair- Recommend status on the PDL as Non-Preferred with Conditions
14. Zymfentra- Recommend status on the PDL as Non-Preferred with Conditions

Lacey Ferguson motioned to accept the recommendations above, and Rachel Kinn seconded. The decision was unanimous.

X. Newly Released Generic Drugs and New Drug Dosage Forms/Strengths/Combinations/BioSimilar (Erin Halverson): All following recommendations were made to maximize cost savings to the program unless otherwise noted.

Drug Name	PDL/RDL Recommendation
Deflazacort	Non-Preferred with Conditions
Gabapentin ER Tablets	Non-Preferred with Conditions
Mirabegron	Non-Preferred
Nitroglycerin Rectal Ointment	Non-Preferred
Sitagliptin	Non-Preferred with Conditions

Drug Name	PDL/RDL Recommendation
Alvaiz	Non-Preferred with Conditions
Hydroxym	Non-Preferred with Conditions
Kionex	Non-Preferred
Libervant	Non-Preferred with Conditions
Myhibbin	Non-Preferred
Rextovy	Preferred
Sovuna	Non-Preferred

Jason Kessler motioned to accept the recommendations in both tables above. Rachel Kinn seconded, and all members were in favor.

- XI. Non-alcoholic Steatohepatitis (NASH) Staff Presentation: Dr. Hedlund reviewed the “Reassessing Human Adipose Tissue” article from *The New England Journal of Medicine*, written by Aaron M. Cypess, M.D., Ph.D.

A motion was made by Jason Kessler to adjourn the meeting. It was seconded by Rachel Kinn, and all in attendance approved. The meeting adjourned at 11:35 a.m. The next scheduled meeting is set for November 21, 2024.